Node metastasis had been significant predictors of PFS. Even so both anti-p53 antibody and IHC of p53 protein negativity didn’t yield any independent predictive components (Table 3).Discussion To our understanding, this retrospective study would be the 1st to evaluate the predictive significance from the presence ofTable 3 Univariate and multivariate analysisUnivariate evaluation OS Gender (male or female) Age (65 or 2^ 65) Performance status (0 or 1) Resection of major tumor (yes or no) Ascitis (yes or no) Liver metastasis (yes or no) Lung metastasis (yes or no) Lymph metastasis (yes or no) Many metastasis (yes or no) Peritoneal metastasis (yes or no) Anti p53 antibody (constructive or adverse) IHC of p53 protein (good or damaging) KRAS (wild or mutant) PFS Gender (male or female) Age (65 or^65) Overall performance status (0 or 1) Resection of principal tumor (yes or no) Ascitis (yes or no) Liver metastasis (yes or no) Lung metastasis (yes or no) Lymph metastasis (yes or no) Many metastasis (yes or no) Peritoneal metastasis (yes or no) Anti p53 antibody (optimistic or adverse) IHC of p53 protein (constructive or damaging) KRAS (wild or mutant) Multivariate analysis OS Peritoneal metastasis (yes or no) PFS Lung metastasis (yes or no) Lymph metastasis (yes or no) 2.46 0.5 HR two.three 1.six 0.99 1.8 1.five 0.6 0.54 two.eight 0.47 0.9 0.73 0.9 1 0.98 HR 0.76 0.98 1.78 0.7 1.7 1.2 0.77 1.9 two.5 two.five 0.eight 0.58 1.anti-p53 antibodies and its correlation together with the KRAS genotype in CRC individuals treated with first-line chemotherapy. No correlation was observed between anti-p53 antibody positivity and ORR. Moreover, no correlation was observed between anti-p53 antibody positivity as well as the KRAS genotype. The mechanism underlying anti-p53 auto-antibody production has but to be revealed but is thought to be linked with the presence from the TP53 mutation and p53 protein overexpression. Anti-p53 autoantibody frequency was then correlated with reported TP53 mutation rates toLower 95 CI 0.34 0.94 0.42 0.two 0.7 0.59 0.34 0.86 1.1 1.two 0.three 0.21 0.Upper 95 CI 1.67 1.03 7.5 1.6 4.1 two.six 1.7 four.two five.9 five.2 1.7 1.6 2.p.value 0.five 0.5 0.43 0.43 0.22 0.55 0.51 0.1 0.03 0.01 0.61 0.three 0.0.9 0.96 0.23 0.72 0.28 0.28 1.59 0.26 0.51 0.37 0.49 0.51 0.three.03 1.02 two.47 three.1 1.43 1 five.2 0.85 1.six 1.45 1.6 1.9 1.0.1 0.53 0.64 0.99 0.29 0.07 4E-04 0.01 0.72 0.27 0.73 0.99 0.94 p.value 0.Reduced 95 CI 1.Upper 95 CI five.1.34 0.4.51 0.0.003 0.Osumi et al. BMC Cancer (2015) 15:Web page 7 ofTable 4 p53 status and prognosis of colorectal cancer: past literature dateReference n Histology treatment Strategies for IHC Sequencing Frequency Prognostic value determing alterd p53 Overall survial Survival p53 Ab pathway ( ) + + + + + + + 37.IL-1 beta Protein MedChemExpress 6(IHC) 41.DKK1 Protein Formulation 8DtHCD 65 OHCD 57 OHCD 51.PMID:23756629 five(IHC) 47(IHC) 32(S) Samowitz WS [16] Chang SC [17] 1464 ACC 167 ACC biopsy and surgery surgery + + + 45.4DSD 28.1(Ab) 56.three(S) Angelopoulou K [18] 229 Kressner U [19] Suppiah A [20] Kreessner U [21] 184 28 294 ACC ACC ACC ACC biopsy and surgery + surgery surgery biopsy + + + 23(Ab) 32(Ab) 21,7(Ab) 55DAbD univariate NA univariate univariate NS univariate murtivariate univariate univariate murtivariate NS univariate NS NS NS NA NS NA NA NA NA NA NA NA NA NA NA Response NALAN YT [10] Triantafyllou K [11] Wang Q [12] Hu J [13] Grewal H [14]258 55 40 120ACCsurgeryAdenoma Polypectomy ACC ACC ACC ACC surgerymurtivariate NA NA NA NA NA NA NA NA NAbiopsy and surgery surgery surgery -Bouzourenne H [15]Ab antibody; IHC immunohistochemistry; S sequencing; ACC advanced colorect.
